20|20 OptimEyes Technologies is a biotechnology spin-out company from McMaster University located in Hamilton, Ontario, Canada. We are developing a transformative drug delivery platform for ocular diseases normally controlled by eye drops.

Using a patent technology formulation, initially targeted for dry eye disease, we are able to change the dosing paradigm from twice daily to once or twice weekly. This will revolutionize treatment for patients, improving their comfort, compliance and clinical outcomes.